Genomic profiling of primary and metastatic thyroid cancers
Autores da FMUP
Participantes de fora da FMUP
- Melo, M
- Zhu, YJ
- Gazzo, A
- Paula, AD
Unidades de investigação
Abstract
The genetic repertoire of primary thyroid cancers (TCs) is well documented, but there is a considerable lack of molecular profiling in metastatic TCs. Here, we retrieved and analyzed the molecular and clinical features of 475 primary and metastatic TCs subjected to targeted DNA sequencing, from the cBioPortal database. The cohort included primary and metastatic samples from 276 papillary thyroid carcinomas (PTCs), 5 follicular thyroid carcinomas, 22 Hurthle cell carcinomas (HCCs), 127 poorly differentiated thyroid carcinomas (PDTCs), 30 anaplastic thyroid carcinomas (ATCs) and 15 medullary thyroid carcinomas. The ATCs had the highest tumor mutational burden and the HCCs the highest fraction of the genome altered. Compared to primary PTCs, the metastases had a significantly higher frequency of genetic alterations affecting TERT (51% vs 77%, P < 0.001), CDKN2A (2% vs 10%, P < 0.01), RET (2% vs 7%, P < 0.05), CDKN2B (1% vs 6%, P < 0.05) and BCOR (0% vs 4%, P < 0.05). The distant metastases had a significantly lower frequency of BRAF (64% vs 85%, P < 0.01) and a significantly higher frequency of NRAS (13% vs 3%, P < 0.05) hotspot mutations than the lymph node metastases. Metastases from HCCs and PDTCs were found to be enriched for NF1 (29%) and TP53 (18%) biallelic alterations, respectively. The frequency of subclonal mutations in ATCs was significantly higher than in PTCs (43% vs 25%, P < 0.01) and PDTCs (43% vs 22%, P < 0.01). Metastatic TCs are enriched in clinically informative genetic alterations such as RET translocations, BRAF hotspot mutations and NF1 biallelic losses that may be explored therapeutically.
Dados da publicação
- ISSN/ISSNe:
- 1351-0088, 1479-6821
- Tipo:
- Article
- Páginas:
- -
- DOI:
- 10.1530/erc-23-0144
- Link para outro recurso:
- www.scopus.com
Endocrine-Related Cancer BioScientifica Ltd.
Citações Recebidas na Web of Science: 4
Citações Recebidas na Scopus: 4
Documentos
- Não há documentos
Filiações
Filiações não disponíveis
Keywords
- thyroid cancers; DNA sequencing; somatic mutations; copy number alterations; distant metastasis
Proyectos asociados
The role of 5-hydroxymethylcytosine as a potential epigenetic biomarker in a large series of thyroid neoplasm.
Investigador Principal: Valdemar de Jesus Conde Máximo
Estudo Clínico Académico (Thyroid neoplasm) . 2023
Mitochondrial complex II genetic characterization and enzymatic expression profile in tumours of the adrenal cortex and medulla
Investigador Principal: Valdemar de Jesus Conde Máximo
Estudo Clínico Académico (Mitochondrial) . 2020
Selenium Clinical Supplementation In Autoimmune Thyroid Disease: A Portuguese Survey
Investigador Principal: Ana Paula Soares Dias Ferreira
Estudo Clínico Académico . 2022
Squamous cell carcinogenesis of the skin: Molecular characterization of prognostic therapeutic biomakers
Investigador Principal: Ana Paula Soares Dias Ferreira
Estudo Clínico Académico . 2022
Clinicopathological features and molecular biomarkers? role predicting papillary thyroid cancer patients? outcome: How to personalize and guide surgical treatment
Investigador Principal: Ana Paula Soares Dias Ferreira
Estudo Clínico Académico . 2022
Role of the MITOchondrial fission protein DRP1 as a prognosis and predictive biomarker in the treatment of differentiated thyroid cancer (ROMITO-DRP1)
Investigador Principal: Valdemar de Jesus Conde Máximo
Estudo Clínico Académico . 2022
Fatores do microambiente tumoral no cancro do ovário.
Investigador Principal: Ana Paula Soares Dias Ferreira
Estudo Clínico Académico . 2022
New Biomarkers development, validation and application in Bladder Cancer.
Investigador Principal: Valdemar de Jesus Conde Máximo
Estudo Clínico Académico . 2021
Citar a publicação
Conde V,Melo M,Zhu YJ,Gazzo A,Simoes MS,Paula AD,Soares Dias Ferreira A. Genomic profiling of primary and metastatic thyroid cancers. Endocr.-Relat. Cancer. 2024. 31. (2):e230144. IF:3,900. (2).